LIVIVO - Search results -

Search results

Result 1 - 10 of total 98

Search options

Article ; Online: Monitored COVID-19 vaccine humoral response in immunocompromised solid organ transplant recipients.

Nikaein, Afzal / Chemmalakuzhy, Ashley / Khan, Salman / Hunt, Judson / Haumpy, Derek / Choudhary, Alok / Pinter, Abraham / Sanchez, Ayrton / Lerman, Mark

Human immunology

2024 Volume 85, Issue 2, Page(s) 110760

Abstract: The SARS-CoV-2 pandemic has resulted in rapid research and vaccine development to help curtail unchecked transmission. However, these studies cannot be applied as easily among every population, such as immunocompromised individuals. In this study, we ... ...

Abstract	The SARS-CoV-2 pandemic has resulted in rapid research and vaccine development to help curtail unchecked transmission. However, these studies cannot be applied as easily among every population, such as immunocompromised individuals. In this study, we observed the humoral response of 70 total heart and renal transplant patients to mRNA SARS-CoV-2 vaccinations to help further understand the effectiveness of vaccination in post-transplant patients following second or booster vaccinations. Antibodies were measured by bead technology to detect IgG, as well as IgG/IgM Rapid Cassette tests for confirmation. Immunocompromised patients had a noticeably lower humoral response than non-immunocompromised populations, with an even lower response among Black patients. Our findings also show for the first time various antibody responses to different motifs of the virus, with the lowest being against the S2 motif. A potential link between the duration of immunosuppression and vaccine response was also observed, where patients on immunosuppressants for longer had a stronger response to vaccination compared to recent transplant patients in our study. In addition, younger transplant recipients had a better humoral response to vaccination, and vaccine effectiveness was disproportionate between races. This finding reinforces the continuation of the guidelines for accelerated vaccination schedules for immunocompromised patients.
MeSH term(s)	Humans ; COVID-19 Vaccines ; Transplant Recipients ; COVID-19 ; SARS-CoV-2 ; Immunocompromised Host ; Kidney Transplantation ; Immunoglobulin G ; Antibodies, Viral ; Vaccination
Chemical Substances	COVID-19 Vaccines ; Immunoglobulin G ; Antibodies, Viral
Language	English
Publishing date	2024-02-02
Publishing country	United States
Document type	Journal Article
ZDB-ID	801524-7
ISSN	1879-1166 ; 0198-8859
ISSN (online)	1879-1166
ISSN	0198-8859
DOI	10.1016/j.humimm.2024.110760
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1597: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Roles of HIV-1 Env variable regions in viral neutralization and vaccine development.

Pinter, Abraham

Current HIV research

2007 Volume 5, Issue 6, Page(s) 542–553

Abstract: A major focus of HIV-1 vaccine development has been directed towards a limited number of broadly conserved epitopes in the Envelope (Env) proteins that are sensitive neutralization targets in many primary isolates. However, evidence suggests that these ... ...

Abstract	A major focus of HIV-1 vaccine development has been directed towards a limited number of broadly conserved epitopes in the Envelope (Env) proteins that are sensitive neutralization targets in many primary isolates. However, evidence suggests that these epitopes are poorly immunogenic; similar antibodies are rarely produced by infected subjects, nor are they induced by various immunogens designed to express these epitopes. On the other hand, the major variable domains of Env are highly immunogenic; antibodies against these regions are common in sera of infected patients and easily generated upon immunization. Although these epitopes are extremely sensitive neutralization targets in some laboratory strains and primary isolates, the neutralization range of antibodies against these sites is limited. This review describes potent neutralization epitopes located in the variable regions of Env and discusses the bases for the limited neutralization breadth of antibodies against these targets. Strategies are discussed for using available information to design immunogens capable of exploiting the potential of these regions as vaccine targets.
MeSH term(s)	AIDS Vaccines/immunology ; Amino Acid Sequence ; Antigen-Antibody Reactions ; Epitope Mapping ; Epitopes/immunology ; HIV Envelope Protein gp120/chemistry ; HIV Envelope Protein gp120/immunology ; HIV Envelope Protein gp41/immunology ; HIV Infections/immunology ; HIV Infections/prevention & control ; HIV-1/immunology ; Humans ; Molecular Sequence Data ; Peptide Fragments/chemistry ; Peptide Fragments/immunology ; env Gene Products, Human Immunodeficiency Virus/immunology
Chemical Substances	AIDS Vaccines ; Epitopes ; HIV Envelope Protein gp120 ; HIV Envelope Protein gp41 ; HIV envelope protein gp120 (135-148) ; HIV envelope protein gp120 (305-321) ; Peptide Fragments ; env Gene Products, Human Immunodeficiency Virus
Language	English
Publishing date	2007-11-26
Publishing country	Netherlands
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2192348-6
ISSN	1873-4251 ; 1570-162X
ISSN (online)	1873-4251
ISSN	1570-162X
DOI	10.2174/157016207782418470
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6102: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Brilacidin, a Non-Peptide Defensin-Mimetic Molecule, Inhibits SARS-CoV-2 Infection by Blocking Viral Entry.

Xu, Chuan / Wang, Annie / Honnen, William / Pinter, Abraham / Weston, Warren K / Harness, Jane A / Narayanan, Aarthi / Chang, Theresa L

EC microbiology

2022 Volume 18, Issue 4, Page(s) 1–12

Abstract: Brilacidin (PMX-30063), a non-peptide defensin-mimetic small molecule, inhibits SARS-CoV-2 viral infection but the anti-viral mechanism is not defined. Here we determined its effect on the specific step of the viral life cycle. Brilacidin blocked SARS- ... ...

Abstract	Brilacidin (PMX-30063), a non-peptide defensin-mimetic small molecule, inhibits SARS-CoV-2 viral infection but the anti-viral mechanism is not defined. Here we determined its effect on the specific step of the viral life cycle. Brilacidin blocked SARS-CoV-2 infection but had no effect after viral entry. Brilacidin inhibited pseudotyped SARS-CoV-2 viruses expressing spike proteins from the P.1 Brazil strain and the B.1.1.7 UK strain. Brilacidin affected viral attachment in hACE2-dependent and independent manners depending on the concentrations. The inhibitory effect on viral entry was not mediated through blocking the binding of either the spike receptor-binding domain or the spike S1 protein to hACE2 proteins. Taken together, brilacidin inhibits SARS-CoV-2 infection by blocking viral entry and is active against SARS-CoV-2 variants.
Language	English
Publishing date	2022-03-08
Publishing country	Scotland
Document type	Journal Article
Database	MEDical Literature Analysis and Retrieval System OnLINE

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Author Correction: Insights into next generation sequencing guided antibody selection strategies.

Erasmus, M Frank / Ferrara, Fortunato / D'Angelo, Sara / Spector, Laura / Leal-Lopes, Camila / Teixeira, André A / Sørensen, Jesper / Nagpal, Suhani / Perea-Schmittle, Kathryn / Choudhary, Alok / Honnen, William / Calianese, David / Antonio Rodriguez Carnero, Luis / Cocklin, Simon / Greiff, Victor / Pinter, Abraham / Bradbury, Andrew R M

Scientific reports

2024 Volume 14, Issue 1, Page(s) 3090

Language	English
Publishing date	2024-02-07
Publishing country	England
Document type	Published Erratum
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-024-53751-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Correction: Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis.

PloS one

2024 Volume 19, Issue 1, Page(s) e0297828

Abstract: This corrects the article DOI: 10.1371/journal.pone.0274415.]. ...

Abstract	[This corrects the article DOI: 10.1371/journal.pone.0274415.].
Language	English
Publishing date	2024-01-23
Publishing country	United States
Document type	Published Erratum
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0297828
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry

Xu, Chuan / Wang, Annie / Marin, Mariana / Honnen, William / Ramasamy, Santhamani / Porter, Edith / Subbian, Selvakumar / Pinter, Abraham / Melikyan, Gregory B. / Lu, Wuyuan / Chang, Theresa L.

Viruses. 2021 June 26, v. 13, no. 7

2021

Abstract: Innate immunity during acute infection plays a critical role in the disease severity of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and is likely to contribute to COVID-19 disease outcomes. Defensins are highly ... ...

Abstract	Innate immunity during acute infection plays a critical role in the disease severity of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and is likely to contribute to COVID-19 disease outcomes. Defensins are highly abundant innate immune factors in neutrophils and epithelial cells, including intestinal Paneth cells, and exhibit antimicrobial and immune-modulatory activities. In this study, we investigated the effects of human α- and β-defensins and RC101, a θ-defensin analog, on SARS-CoV-2 infection. We found that human neutrophil peptides (HNPs) 1–3, human defensin (HD) 5 and RC101 exhibited potent antiviral activity against pseudotyped viruses expressing SARS-CoV-2 spike proteins. HNP4 and HD6 had weak anti-SARS-CoV-2 activity, whereas human β-defensins (HBD2, HBD5 and HBD6) had no effect. HNP1, HD5 and RC101 also inhibited infection by replication-competent SARS-CoV-2 viruses and SARS-CoV-2 variants. Pretreatment of cells with HNP1, HD5 or RC101 provided some protection against viral infection. These defensins did not have an effect when provided post-infection, indicating their effect was directed towards viral entry. Indeed, HNP1 inhibited viral fusion but not the binding of the spike receptor-binding domain to hACE2. The anti-SARS-CoV-2 effect of defensins was influenced by the structure of the peptides, as linear unstructured forms of HNP1 and HD5 lost their antiviral function. Pro-HD5, the precursor of HD5, did not block infection by SARS-CoV-2. High virus titers overcame the effect of low levels of HNP1, indicating that defensins act on the virion. HNP1, HD5 and RC101 also blocked viral infection of intestinal and lung epithelial cells. The protective effects of defensins reported here suggest that they may be useful additives to the antivirus arsenal and should be thoroughly studied.
Keywords	COVID-19 infection ; Severe acute respiratory syndrome coronavirus 2 ; antiviral properties ; epithelium ; humans ; innate immunity ; intestines ; lungs ; neutrophils ; peptides ; virion ; viruses
Language	English
Dates of publication	2021-0626
Publishing place	Multidisciplinary Digital Publishing Institute
Document type	Article
ZDB-ID	2516098-9
ISSN	1999-4915
ISSN	1999-4915
DOI	10.3390/v13071246
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article ; Online: Insights into next generation sequencing guided antibody selection strategies.

Scientific reports

2023 Volume 13, Issue 1, Page(s) 18370

Abstract: Therapeutic antibody discovery often relies on in-vitro display methods to identify lead candidates. Assessing selected output diversity traditionally involves random colony picking and Sanger sequencing, which has limitations. Next-generation sequencing ...

Abstract	Therapeutic antibody discovery often relies on in-vitro display methods to identify lead candidates. Assessing selected output diversity traditionally involves random colony picking and Sanger sequencing, which has limitations. Next-generation sequencing (NGS) offers a cost-effective solution with increased read depth, allowing a comprehensive understanding of diversity. Our study establishes NGS guidelines for antibody drug discovery, demonstrating its advantages in expanding the number of unique HCDR3 clusters, broadening the number of high affinity antibodies, expanding the total number of antibodies recognizing different epitopes, and improving lead prioritization. Surprisingly, our investigation into the correlation between NGS-derived frequencies of CDRs and affinity revealed a lack of association, although this limitation could be moderately mitigated by leveraging NGS clustering, enrichment and/or relative abundance across different regions to enhance lead prioritization. This study highlights NGS benefits, offering insights, recommendations, and the most effective approach to leverage NGS in therapeutic antibody discovery.
MeSH term(s)	High-Throughput Nucleotide Sequencing/methods ; Antibodies/genetics ; Epitopes
Chemical Substances	Antibodies ; Epitopes
Language	English
Publishing date	2023-10-26
Publishing country	England
Document type	Journal Article
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-023-45538-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Author Correction: Insights into next generation sequencing guided antibody selection strategies.

Scientific reports

2023 Volume 13, Issue 1, Page(s) 22616

Language	English
Publishing date	2023-12-18
Publishing country	England
Document type	Published Erratum
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-023-49214-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Predictors of chronic COVID-19 symptoms in a community-based cohort of adults.

Silverberg, Jonathan I / Zyskind, Israel / Naiditch, Hiam / Zimmerman, Jason / Glatt, Aaron E / Pinter, Abraham / Theel, Elitza S / Joyner, Michael J / Hill, D Ashley / Lieberman, Miriam R / Bigajer, Elliot / Stok, Daniel / Frank, Elliot / Rosenberg, Avi Z

PloS one

2022 Volume 17, Issue 8, Page(s) e0271310

Abstract: Background: COVID-19 can cause some individuals to experience chronic symptoms. Rates and predictors of chronic COVID-19 symptoms are not fully elucidated.: Objective: To examine occurrence and patterns of post-acute sequelae of SARS-CoV2 infection ( ... ...

Abstract	Background: COVID-19 can cause some individuals to experience chronic symptoms. Rates and predictors of chronic COVID-19 symptoms are not fully elucidated. Objective: To examine occurrence and patterns of post-acute sequelae of SARS-CoV2 infection (PASC) symptomatology and their relationship with demographics, acute COVID-19 symptoms and anti-SARS-CoV-2 IgG antibody responses. Methods: A multi-stage observational study was performed of adults (≥18 years) from 5 US states. Participants completed two rounds of electronic surveys (May-July 2020; April-May 2021) and underwent testing to anti-SARS-CoV-2 nucleocapsid protein IgG antibody testing. Latent Class Analysis was used to identify clusters of chronic COVID-19 symptoms. Results: Overall, 390 adults (median [25%ile, 75%ile] age: 42 [31, 54] years) with positive SARS-CoV-2 antibodies completed the follow-up survey; 92 (24.7%) had ≥1 chronic COVID-19 symptom, with 11-month median duration of persistent symptoms (range: 1-12 months). The most common chronic COVID-19 symptoms were fatigue (11.3%), change in smell (9.5%) or taste (5.6%), muscle or joint aches (5.4%) and weakness (4.6%). There were significantly higher proportions of ≥1 persistent COVID-19 symptom (31.5% vs. 18.6%; Chi-square, P = 0.004), and particularly fatigue (15.8% vs. 7.3%, P = 0.008) and headaches (5.4% vs. 1.0%, P = 0.011) in females compared to males. Chronic COVID-19 symptoms were also increased in individuals with ≥6 acute COVID-19 symptoms, Latent class analysis revealed 4 classes of symptoms. Latent class-1 (change of smell and taste) was associated with lower anti-SARS-CoV-2 antibody levels; class-2 and 3 (multiple chronic symptoms) were associated with higher anti-SARS-CoV-2 antibody levels and more severe acute COVID-19 infection. Limitations: Ambulatory cohort with less severe acute disease. Conclusion: Individuals with SARS-CoV-2 infection commonly experience chronic symptoms, most commonly fatigue, changes in smell or taste and muscle/joint aches. Female sex, severity of acute COVID-19 infection, and higher anti-SARS-CoV-2 IgG levels were associated with the highest risk of having chronic COVID-19 symptoms.
MeSH term(s)	Adult ; Antibodies, Viral ; COVID-19 ; Fatigue ; Female ; Humans ; Immunoglobulin G ; Male ; Pain ; RNA, Viral ; SARS-CoV-2
Chemical Substances	Antibodies, Viral ; Immunoglobulin G ; RNA, Viral
Language	English
Publishing date	2022-08-04
Publishing country	United States
Document type	Journal Article ; Observational Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0271310
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2.

Ukey, Rahul / Bruiners, Natalie / Mishra, Hridesh / Mishra, Pankaj K / McCloskey, Deborah / Onyuka, Alberta / Chen, Fei / Pinter, Abraham / Weiskopf, Daniela / Sette, Alessandro / Roy, Jason / Gaur, Sunanda / Gennaro, Maria Laura

BMC medicine

2022 Volume 20, Issue 1, Page(s) 32

Abstract: Background: Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based ... ...

Abstract	Background: Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines. Main body: We investigated the immunogenicity of Ad26.COV2.S and mRNA vaccines in 33 subjects vaccinated with either vaccine class 5 months earlier on average. After controlling for the time since vaccination, Spike-binding antibody and neutralizing antibody levels were higher in the mRNA-vaccinated subjects, while no significant differences in antigen-specific B cell and T cell responses were observed between the two groups. Conclusions: A dichotomy exists between the humoral and cellular responses elicited by the two vaccine classes. Testing only for humoral responses to compare the durability of SARS-CoV-2 vaccine-induced responses, as typically performed for public health and research purposes, is insufficient.
MeSH term(s)	Ad26COVS1 ; Antibodies, Viral ; COVID-19 ; COVID-19 Vaccines ; Humans ; Immunity, Humoral ; RNA, Messenger/genetics ; SARS-CoV-2 ; Vaccination ; mRNA Vaccines
Chemical Substances	Ad26COVS1 ; Antibodies, Viral ; COVID-19 Vaccines ; RNA, Messenger ; mRNA Vaccines
Language	English
Publishing date	2022-01-25
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2131669-7
ISSN	1741-7015 ; 1741-7015
ISSN (online)	1741-7015
ISSN	1741-7015
DOI	10.1186/s12916-022-02252-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito